SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is experiencing sustained momentum driven by a growing community focused on celebrating cannabis culture and the plant's medicinal potential. Enthusiasts are actively coordinating to build a long-term presence on-chain, emphasizing the project's steady progress and the anticipation surrounding the annual 4/20 cultural milestones.

Bakkt, Inc. is building the backbone of next-generation financial infrastructure. The company provides solutions that enable institutional participation in the digital asset economy, spanning Bitcoin, tokenization, stablecoin payments, and AI-driven finance. Bakkt was founded in 2018 and is headquartered in New York, NY.

Bakkt Inc. - Ordinary Shares - Class A

Bakkt Holdings Inc

Bakkt is drawing significant attention as investors react to a strategic acquisition and persistent rumors of potential partnerships, with community sentiment fueled by the stock's high volatility and strong correlation to Bitcoin's price action. While some traders are focused on a potential short squeeze or a broader institutional re-rating, others remain cautious, debating the long-term impact of share dilution and the company's ability to execute on its pivot toward stablecoin settlement and institutional infrastructure.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing intense community focus as traders speculate on its potential for human identity verification and its role in an increasingly AI-driven digital economy. The conversation is heavily centered on its utility as a 'Proof of Personhood' solution and the impact of recent treasury initiatives and institutional interest surrounding the project.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by regional conflict in the Middle East and concerns over the stability of the Strait of Hormuz. The community is actively debating the impact of potential supply disruptions against the backdrop of broader economic uncertainty, with traders sharply divided between bullish expectations for continued energy price spikes and bearish concerns regarding aggressive market manipulation and speculative bubbles.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining significant traction as a key infrastructure provider in the DeFi space, with community sentiment fueled by its role in the Real World Asset (RWA) narrative and its integration of institutional-grade financial data. Investors are actively discussing the protocol's revenue-sharing model through token buybacks and its unique utility in supplying government-validated macroeconomic data to blockchain ecosystems.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF (DIA) is trending as the broader market grapples with extreme volatility driven by the escalating conflict in Iran, which has sparked fears over oil supply and global shipping routes. Investors are closely monitoring erratic signals from the Trump administration regarding the conflict and energy supply, while debating the long-term economic impacts of rising inflation and geopolitical instability.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors position themselves for a significant PDUFA date on May 31, 2026, for its lead ADHD candidate, CTx-1301. The community is actively discussing the stock's low float, recent financing activities, and the anticipated news regarding U.S. patent approvals for its Precision Timed Release technology.

FIS Trust - FIS Christian Stock Shares of beneficial interest

SHP ETF Trust - FIS Biblically Responsible Risk Managed ETF

Investors are actively debating the intersection of personal faith and portfolio management, with many sharing scripture and reflections on ethical investing within the PRAY ETF community. While some participants are discussing the fund's alignment with their values, others are using the platform as a space to share personal motivations for market participation and conservative lifestyle principles.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is gaining significant momentum as investors pivot toward its long-term potential as an AI and energy-infrastructure company rather than just an EV manufacturer. The community is actively discussing the company's recent expansion of its battery-swapping network and its strategic move into self-developed AI chips, with many looking toward upcoming vehicle delivery milestones as a key catalyst to drive the share price through current resistance levels.

ProShares Trust - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is trending as investors aggressively hedge against heightened geopolitical risks, including escalating tensions with Iran and uncertainty surrounding new trade tariff policies. The community is actively debating the volatility ETF's structural decay, with many traders using it as a tactical tool to capitalize on daily market swings and anticipated macro-economic shocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Gyre Therapeutics subsequently said that it has entered into an agreement to acquire Cullgen in an all-stock transaction valued at about $300 million.</li><li>Under the terms of the merger deal, Cullgen will become a wholly owned subsidiary of Gyre.</li><li>Meanwhile, Pulmatrix said that it continues to pursue alternative merger opportunities.</li></ul>Shares of Pulmatrix, Inc. (PULM), slumped 36% on Monday after the company said that its merger agreement with privately-held pharmaceutical company Cullgen Inc has been terminated.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities-302700613.html">said</a> that Cullgen notified it of the deal termination on Feb. 28. The two companies had entered a merger deal in November 2024 and modified it in December 2025 to allow each party to explore alternate transactions. The company added that it did not receive necessary approval from China Security Regulatory Commission for the deal at the time of Cullgen’s agreement termination.Gyre Therapeutics, Inc. (GYRE) subsequently <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/02/3247348/0/en/Gyre-Therapeutics-Enters-into-Agreement-to-Acquire-Cullgen-to-Gain-Targeted-Protein-Degradation-Platform-and-Pipeline.html">said</a> that it has entered into an agreement to acquire Cullgen in an all-stock transaction valued at about $300 million.<h2 class="st-heading-2">Gyre-Cullgen Deal</h2>Cullgen is focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies. &nbsp;Under the terms of the merger deal, Cullgen will become a wholly owned subsidiary of Gyre.The transaction is expected to close early in the second quarter of 2026, subject to customary closing conditions, including necessary regulatory approvals in the U.S.Following the closure of the acquisition, the new combined entity will be a fully integrated biopharmaceutical company with U.S.- and China-based capabilities spanning from discovery to manufacturing and commercialization and covering multiple therapeutic areas including inflammatory diseases, cancers, and pain, the company said.Shares of GYRE rallied 8% at the time of writing.<h2 class="st-heading-2">Path Ahead For Pulmatrix</h2>Meanwhile, Pulmatrix said that it continues to pursue alternative merger opportunities."Due to the significant delays at the Chinese Regulatory Authority (CSRC) in 2025, we initiated a process earlier this year to identify an alternative reverse merger opportunity for the Company, and we are encouraged by both the interest we've had to date as well as the recent increase in transaction activity within our industry," the company’s interim CEO Peter Ludlum said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GYRE rose from ‘Neutral’ to ‘Bullish’ territory over the past 24 hours, while message volume remained at ‘Normal’ levels.Meanwhile, sentiment around PULM stayed ‘bullish,’ accompanied by ‘high’ message volume.<a href="https://stocktwits.com/symbol/GYRE">Shares of GYRE</a> lost 22% over the past 12 months. <a href="https://stocktwits.com/symbol/PULM">PULM stock</a> dipped 75% in the meantime.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slumps-whats-driving-the-sell-off/cZd3gYYRI27">TLRY Stock Slumps 4%: What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Gyre Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead

Pulmatrix said that Cullgen notified it of the termination of the deal between them on Feb. 28.

Equity

Pulmatrix said that Cullgen notified it of the termination of the deal between them on Feb. 28.


Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of...

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results PR Newswire FRAMINGHAM, Mass., Feb. 26, 2026 Plans to...

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for...

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 and is headquartered in Framingham, MA.

PULM
Pulmatrix Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PULM News

PULMPulmatrix Inc